Drug Development · global
Investigational Celiac Disease Drug FB102 Meets Phase 2 Primary Endpoint, Showing Potential to Reduce Gluten-Induced Intestinal Damage
A trial involving 126 adults provides preliminary evidence of intestinal protection in people with celiac disease; however, the extent of protection, degree of symptom improvement, and long-term safety remain to be clarified by the full data.
For people with celiac disease, avoiding gluten is a line of defense in everyday life: an immune response triggered by diet can damage small intestinal tissue. Whether medication can reduce this damage is a question new therapies aim to answer. On October 8, argenx announced that its experimental antibody FB102 met the primary endpoint in a Phase 2 trial, showing potential to protect the intestine under controlled gluten exposure conditions.
The randomized, placebo-controlled trial enrolled 126 adults, assigned in a 2:2:1 ratio to receive one of two doses of intravenous FB102 or placebo. The study included an eight-week gluten challenge, in which participants were exposed to gluten under trial conditions to assess whether the drug could reduce the resulting intestinal damage.
The primary assessment focused on intestinal tissue structure, measured by the change from baseline in the ratio of villous height to crypt depth. According to the company announcement, the comparison between FB102 and placebo reached statistical significance, with a p-value of 0.0176. However, this number alone does not indicate the magnitude of the protective effect; the actual changes in each group, the size of the difference, and confidence intervals are still needed to determine the clinical significance of the results.
A republication of the company announcement on MarketScreener also stated that intraepithelial lymphocyte (IEL) density, the VCIEL composite score, and symptom outcomes were all directionally consistent with the primary endpoint. This adds support to the signal of tissue protection, but there are currently insufficient details to assess the degree of symptom improvement or whether the two doses produced different effects. This republication and the original report both derive from the company announcement and do not constitute independent verification.
FB102 is an antibody targeting CD122, representing a new drug strategy for celiac disease that acts on an immune-related target. These results address short-term tissue protection under a specific gluten challenge. They do not yet support an inference that patients can relax dietary restrictions, nor do they establish whether the effect can extend to long-term, occasional exposure in everyday life.
Regarding safety, argenx said no new safety signals emerged, but full adverse event data are still needed to assess event frequency, severity, and differences between doses. The company plans to advance Phase 3 development and present detailed results at an upcoming medical meeting. FB102 has received Fast Track designation from the U.S. Food and Drug Administration for the celiac disease indication; this provides support for development and review and does not equate to approval. The key in the next stage is to confirm whether this signal of tissue protection can translate into sustained, clinically meaningful benefit for patients.